Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Penn to receive $467M under settlement with BioNTech over Covid-19 vaccine royalties
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
Hosted on MSN2d
BioNTech Stock In Focus After $791.5M Settlement With NIH: Retail Cautious
Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...
NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley
Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania ...
BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
gulftoday2d
BioNTech settles millions’ royalty issue
Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...
BioNTech SE ADR rises Friday, outperforms market
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
BioNTech Enters Into Settlements With U.S. Agency, UPenn Over COVID-19 Vaccine Royalties
Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...
Pharmaceutical Technology1d
BNT-321 by BioNTech for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.
BioNTech SE ADR falls Thursday, underperforms market
The ADR's fall snapped a three-day winning streak.
Reuters5d
BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
Dec 27 (Reuters) - BioNTech (22UAy.DE), opens new tab has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the ...